<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Carlos Hojaij’s comment</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Carlos Hojaij’s comment" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2018-04-03T00:32:10+00:00" />
<meta name="DC.date" content="2018-04-03T00:32:10+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEXB724.HTM?id=2329" />
<link rel="next" href="INDEX0103.HTM?id=2573" />
<link rel="canonical" href="INDEXA070.HTM?id=2446" />



</head>
<body id="pageUID-2446">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li id="current"><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEXAF9F.HTM?id=355" target="_self">Controversies</a>&nbsp;/&nbsp;<a href="INDEXB724.HTM?id=2329" target="_self">Donald F. Klein, Max Fink, Edward Shorter and Thomas A. Ban: Comment exchange on Flagrant Catatonic Behavior.</a>&nbsp;/&nbsp;Carlos Hojaij’s comment</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Controversies</li><li><a href="INDEX01FF.HTM?id=3395" target="_self">Jay D. Amsterdam and Leemon B. McHenry: The Paroxetine 352 Bipolar Study Revisited: Deconstruction of Corporate and Academic Misconduct.</a><span class="hidden">.</span></li><li><a href="INDEXC230.HTM?id=486" target="_self">Thomas A. Ban: Conflict of interest in neuropsychopharmacology</a><span class="hidden">.</span></li><li><a href="INDEX2AF5.HTM?id=1342" target="_self">Thomas A. Ban: Development of our Vocabulary</a></li><li><a href="INDEX1BE7.HTM?id=3220" target="_self">Thomas A. Ban:  Education in Biological Psychiatry – Homage to Dr. Heinz E. Lehmann</a></li><li><a href="INDEXFB00.HTM?id=829" target="_self">Barry Blackwell: Adumbration; A history lesson</a><span class="hidden">.</span></li><li><a href="INDEX7196.HTM?id=3970" target="_self">Barry Blackwell: A Tale of Two Pioneers.</a></li><li><a href="INDEXD39F.HTM?id=1665" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry</a><span class="hidden">.</span></li><li><a href="INDEXF833.HTM?id=1944" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry. Revised</a><span class="hidden">.</span></li><li><a href="INDEX8B56.HTM?id=778" target="_self">Barry Blackwell: The anxiety enigma</a><span class="hidden">.</span></li><li><a href="INDEX8B7A.HTM?id=2096" target="_self">Barry Blackwell: The Baby and The Bath Water</a><span class="hidden">.</span></li><li><a href="INDEX07C2.HTM?id=622" target="_self">Barry Blackwell: The lithium controversy: A historical autopsy</a><span class="hidden">.</span></li><li><a href="INDEX12D3.HTM?id=1369" target="_self">Pierre Baumann and Francois Ferrero: An official inqury of the clinical research activities (1946-1972) of Roland Kuhn (1912-2005)</a><span class="hidden">.</span></li><li><a href="INDEXA7C8.HTM?id=2954" target="_self">John Court: A note on the history of Anorexia Nervosa</a></li><li><a href="INDEX32F0.HTM?id=421" target="_self">Paul Devenyi: Addictions are not treatable diseases</a><span class="hidden">.</span></li><li><a href="INDEXE29D.HTM?id=477" target="_self">Paul Devenyi: Pharmacotherapy of addictions</a></li><li><a href="INDEXC591.HTM?id=3315" target="_self">Camille Drach Hojaij: Stein and Empathic Fulfilment.</a><span class="hidden">.</span></li><li><a href="INDEX3CB5.HTM?id=2526" target="_self">François Ferrero: Inquiry of the Geneva 1980s’ Psychiatry Crisis</a><span class="hidden">.</span></li><li><a href="INDEXC947.HTM?id=3727" target="_self">Max Fink: Reconceptualization of Catatonia.</a><span class="hidden">.</span></li><li><a href="INDEX3D6D.HTM?id=2322" target="_self">Ernst J. Franzek: From the dichotomy to a three-part grouping of endogenous psychoses</a><span class="hidden">.</span></li><li><a href="INDEX031F.HTM?id=3472" target="_self">Samuel Gershon: Brintellix  -  votioxetine</a></li><li><a href="INDEXCD60.HTM?id=3191" target="_self">Samuel Gershon: Device for naltrexone delivery</a></li><li><a href="INDEX8E42.HTM?id=3064" target="_self">Samuel Gershon: Ketamine, the “new” breakthrough in the treatment of depression</a><span class="hidden">.</span></li><li><a href="INDEX1823.HTM?id=2488" target="_self">Samuel Gershon: Lithium history</a><span class="hidden">.</span></li><li><a href="INDEX5D83.HTM?id=3646" target="_self">Samuel Gershon: The emergence of “new” drugs in recent years.</a></li><li><a href="INDEXFA6F.HTM?id=3375" target="_self">Samuel Gershon: The Tacrine paradigm.</a><span class="hidden">.</span></li><li><a href="INDEXF3E3.HTM?id=670" target="_self">Samuel Gershon: The trazodone cntrovery and its potential fatal consequences</a></li><li><a href="INDEX4A93.HTM?id=2894" target="_self">Ken Gillman: Medical science publishing: A slow-motion train wreck</a><span class="hidden">.</span></li><li><a href="INDEXDBE8.HTM?id=3720" target="_self">David Healy: Do Randomized Controlled Trials Add to or Subtract from Clinical Knowledge?</a><span class="hidden">.</span></li><li><a href="INDEX3202.HTM?id=1350" target="_self">David Healy: The shipwreck of the singular</a><span class="hidden">.</span></li><li><a href="INDEX2555.HTM?id=2447" target="_self">Hanfried Helmchen: The role of psychopharmacotherapy in the early development of social psychiatry in Germany</a><span class="hidden">.</span></li><li><a href="INDEXE41A.HTM?id=2095" target="_self">Carlos R. Hojaij: A Psychopathological Marker For Biological Psychiatry:  The Point of No Return and the “Something New&quot; *</a></li><li><a href="INDEX4C30.HTM?id=1823" target="_self">Carlos R. Hojaij: “DSM-5: The Future of Psychiatric Diagnosis” or Continuing the Psychiatry DiSMantlement</a><span class="hidden">.</span></li><li><a href="INDEX14F7.HTM?id=2103" target="_self">Carlos R. Hojaij: Psychiatry and Medicine</a></li><li><a href="INDEX711C.HTM?id=2118" target="_self">Carlos R. Hojaij: Towards a Psychiatric Biology</a></li><li><a href="INDEX61B8.HTM?id=3147" target="_self">David Janowsky: Cholinergic muscarinic mechanisms in depression and mania</a><span class="hidden">.</span></li><li><a href="INDEXC12C.HTM?id=3956" target="_self">Daniel Kanofsky and Mary E. Woesner: A Fresh Air Approach to COVID-19.</a><span class="hidden">.</span></li><li><a href="INDEX0B8F.HTM?id=530" target="_self">Martin M. Katz: Component-Specific vs. Diagnosis-Specific Clinical Trial in Depression</a><span class="hidden">.</span></li><li><a href="INDEXBDA3.HTM?id=594" target="_self">Martin M. Katz: Multivantaged vs. conventional assessment method</a><span class="hidden">.</span></li><li><a href="INDEX46C5.HTM?id=496" target="_self">Martin M. Katz: Onset of clinical action of antidepressants</a><span class="hidden">.</span></li><li><a href="INDEX94E9.HTM?id=1147" target="_self">Martin  M. Katz: The need and rationale for shortenng the clinical trial for antidepressants</a></li><li><a href="INDEXB724.HTM?id=2329" target="_self">Donald F. Klein, Max Fink, Edward Shorter and Thomas A. Ban: Comment exchange on Flagrant Catatonic Behavior.</a><span class="hidden">.</span><ul><li><strong>Carlos Hojaij’s comment</strong></li><li><a href="INDEX0103.HTM?id=2573" target="_self">Max Fink’s reply to Carlos Hojaij’s comment</a><span class="hidden">.</span></li><li><a href="INDEX8B8C.HTM?id=2588" target="_self">Donald Klein’s reply to Carlos Hojaij’s comment</a><span class="hidden">.</span></li><li><a href="INDEX3D3E.HTM?id=2998" target="_self">Hector Warnes’ general comment on the catatonic type of schizophrenia</a></li></ul></li><li><a href="INDEXA16A.HTM?id=1625" target="_self">Joseph Knoll: Controversies on selegiline/(-)-deprenyl’s  pharmacological spectrum after more than 50 years of its development</a></li><li><a href="INDEX98B4.HTM?id=2771" target="_self">Magda Malewska-Kasprzak, Agnieszka Permoda-Osip, Janusz Rybakowski:Disturbances of the purinergic system in affective disorders and schizophrenia</a><span class="hidden">.</span></li><li><a href="INDEXBB29.HTM?id=4134" target="_self">Trudo Lemmens. “Medical Assistance in Dying” (Euthanasia and Assisted Suicide) in Canada: A Case Raises Questions About Its Use in Patients with Disability and Mental Illness.</a><span class="hidden">.</span></li><li><a href="INDEXEBA9.HTM?id=3891" target="_self">Amy S. F. Lutz: The Rise and Fall of the Dexamethasone Suppression Test: Stability, Consensus, Closure.</a><span class="hidden">.</span></li><li><a href="INDEX41D4.HTM?id=3252" target="_self">Gin S. Malhi: A critical analysis of concepts in psychiatry</a><span class="hidden">.</span></li><li><a href="INDEXD25B.HTM?id=2701" target="_self">Antonio E. Nardi, Richard Balon, Guy Chouinard, Fiammetta Cosci, Steven Dubovsky, Giovanni A. Fava, Rafael C. Freire, David J. Greenblatt, John H. Krystal, Karl Rickels, Thomas Roth, Carl Salzman, Richard I. Shader, Edward K. Silberman, Nicoletta Sonino,</a><span class="hidden">.</span></li><li><a href="INDEX4CFC.HTM?id=2972" target="_self">János Radó: Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment</a><span class="hidden">.</span></li><li><a href="INDEXD26F.HTM?id=3140" target="_self">Janos Radó: Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus. Review of the literature</a><span class="hidden">.</span></li><li><a href="INDEX13F5.HTM?id=1248" target="_self">Shridhar Sharma: Insulin coma treatment: Facts and controversies</a><span class="hidden">.</span></li><li><a href="INDEX5461.HTM?id=390" target="_self">Edward Shorter: The Q-T interval and the Mellaril story - a cautionary tale</a><span class="hidden">.</span></li><li><a href="INDEX70B9.HTM?id=2755" target="_self">Leonardo Tondo: Brief History of Suicide in Western Cultures</a><span class="hidden">.</span></li><li><a href="INDEX7938.HTM?id=2000" target="_self">Hector Warnes: The gut-brain axis</a><span class="hidden">.</span></li><li><a href="INDEXEABE.HTM?id=3450" target="_self">Hector Warnes: Pyridoxine in the treatment of lithium-induced tremor.</a><span class="hidden">.</span></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><div id="c4269" class="csc-default"><h1><b>Carlos Hojaij’s comment on Donald F. Klein, Max Fink, Edward Shorter and Thomas A. Ban’s Comment Exchange on Flagrant Catatonic Behavior</b></h1>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; I was invited to participate in this exchange under the title of &quot;Flagrant Catatonic Behavior.”</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; According to the English Cambridge Dictionary,&nbsp; “flagrant” means &quot;shocking because of being so obvious” (so intense and evident like the light of a fire). I mention the definition of “flagrant” because, in contrast, we may find catatonic manifestation that is very discreet (subtle), like a simple repetitive finger movement, or a reiterated word present in an extended speech disconnected to the whole context.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Automatically, I went back to my years at the Hospital Franco da Rocha (also known as <i>Hospital do Juqueri</i>), a psychiatric institution founded by Dr. Franco da Rocha in the late 19<sup>th</sup> century, 40 km from the city of São Paulo (Brazil), where I studied and worked for years. At that time the hospital complex was composed of several buildings for acute patients and colonies (farm houses) for chronic patients. In 1970s the total population was 11,000 patients! Anyone interested in psychiatry could see anything and everything. I used to take few hours each week to just observe how the patients behaved when outside in the courtyard of the buildings. Of course, I recognized many patients with catatonic signs of all sorts: pacing up and down; sitting for hours in the same position and at the same local, everyday; suddenly standing up and running around a tree; walking while counting the steps and making extravagant gestures with the arms and face; in an absolute mutism, static, not responding to any exterior stimulus; in echopraxia; and in active and passive negativisms. A hospital document from early 1900s describes how an agitated and aggressive patient, having an explosive reaction, rushed to a patient who was in a stuporous state and hit him in the abdomen; the catatonic felt unconscious for few minutes; then, stood up and started walking regularly with an expression of pain but talking to others; this case, known as the “masso-therapy” (boulder-therapy), was registered before the advent of ECT! There was a patient who used to go to the Director's office (he allowed the patient to do so) and for hours would stand beside his desk and move his trunk as a pendulum, while rigidly maintaining his head, face and arms (he was known as “the director's clock”). </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During interviews I had numerous opportunities to observe different stereotypic movements, as well as echolalia, echopraxia and &quot;flexibilitas cerea.” I observed patients going from hyperkinesia to total akinesia (almost like an amentia state); others presented an association of a general akinesia and a localized repetitive movement, like that of just of one finger; and patients with partial catatonic remission, all without any significant treatment. I also observed paranoid patients progressing to catatonia, and vice-versa. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By the time I left the Hospital Franco da Rocha, and in the early ‘80s concentrated my teaching in another public hospital in São Paulo with 200 patients (acute and chronic), the catatonic patients became less and less frequent to my sight. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In my private practice (since 1969) I had few schizophrenic catatonic patients, fortunately with favorable outcomes, at least regarding the catatonic symptoms. Association of ECT and haloperidol showed significant degree of effectiveness. However, during these last 20 years working in Australia, I do not remember having seen a catatonic patient in my private practice (which includes in-patients). Of course, I am not mentioning here the cases of organic brain syndrome, or acute psych-organic reactions (Bleuler, Willi and Bülher 1968), etc.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; My main professor of psychiatry, Paulo Fraletti, an inveterate adept of German psychiatry, used to say that some catatonia has a psychogenic factor (he never told me from where and how he formulated this idea). According to my experience, however, and considering the significant reduction of catatonias in the last decades, I may speculate that - like hebephrenic schizophrenia - there are environmental factors influencing the manifestation of catatonic signs/symptoms (here I am excluding the cases of definitive functional disorders and pathologies, i.e., neurological, endocrine, infectious, etc.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; En passant, anyone could question the evolution of R. Gjessing’s (Minde 1966) periodic catatonia hypothesis: are catatonic stupor and catatonic excitement symptoms of a basic similar pathophysiological process linked to nitrogen fluctuation? Of course, to begin is like trying to answer the question: which one comes first, the egg or the chicken? Maybe research like that outlined in the abstract below (Balint et al. 2018) could help us.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saying all this, I am not sure whether early treatment does not prevent catatonia from appearing in the course of schizophrenia, as happens with hallucinations and delusions that are aborted by the so-called anti-psychotics, or environmental factors from this agitated world may be providing enough stimulus to counterpose the catatonic functional mechanism.&nbsp; </p>
<p>&nbsp;</p>
<p><b>Abstract </b></p>
<p><b>(Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology)</b></p>
<p>&nbsp;</p>
<p>Movement disorders are a prominent and common feature in many autoantibody-associated neurological diseases, a group of potentially treatable conditions that can mimic infectious, metabolic or neurodegenerative disease. Certain movement disorders are likely to associate with certain autoantibodies; for example, the characteristic dyskinesias, chorea and dystonia associated with NMDAR antibodies, stiff person spectrum disorders with GAD, glycine receptor, amphiphysin or DPPX antibodies, specific paroxysmal dystonias with LGI1 antibodies, and cerebellar ataxia with various anti-neuronal antibodies. There are also less-recognized movement disorder presentations of antibody-related disease, and a considerable overlap between the clinical phenotypes and the associated antibody spectra. In this review, we first describe the antibodies associated with each syndrome, highlight distinctive clinical or radiological ‘red flags’, and suggest a syndromic approach based on the predominant movement disorder presentation, age, and associated features. We then examine the underlying immunopathophysiology, which may guide treatment decisions in these neuroimmunological disorders, and highlight the exceptional interface between neuronal antibodies and neurodegeneration, such as the tauopathy associated with IgLON5 antibodies. Moreover, we elaborate the emerging pathophysiological parallels between genetic movement disorders and immunological conditions, with proteins being either affected by mutations or targeted by autoantibodies. Hereditary hyperekplexia, for example, is caused by mutations of the alpha subunit of the glycine receptor leading to an infantile-onset disorder with exaggerated startle and stiffness, whereas antibodies targeting glycine receptors can induce acquired hyperekplexia. The spectrum of such immunological and genetic analogies also includes cerebellar ataxias and some encephalopathies. Lastly, we discuss how these pathophysiological considerations could reflect on possible future directions regarding antigen-specific immunotherapies or targeting the pathophysiological cascades downstream of the antibody effects.</p>
<p>&nbsp;</p>
<p><b>References:</b> </p>
<p>Balint B, Vincent A, Meinck HM, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.&nbsp; Brain, Volume 141, Issue 1, 1 January 2018, pp. 13–36.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><a name="_Hlk508348344">Bleuler M, Willi J, Bülher, HD</a>. <i>Concepción de Bonhoeffer sobre el tipo de reacción exógena aguda.</i> In: Desarrollo y Estado Actual de Nuestros Conocimientos. Sindromes Psiquicos Agudos en Las Enfermedades Somaticas. Ediciones Morata, Madrid, 1968; pp 1-31.</p>
<p>&nbsp;</p>
<p>Minde K. Periodic catatonia, a review with special reference to Roly Guessing. The Canadian Psychiatric Association Journal / <i>La Revue de L’Association des psychiatres du Canada</i>. 1996; 11 (5), 421-425. April 5, 2018.</p>
<p>&nbsp;</p>
<p>April 5, 2018</p></div><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>